Hansa Biopharma AB (publ) (FRA:24H)
2.972
-0.094 (-3.07%)
At close: Dec 1, 2025
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 30.80M SEK in the quarter ending September 30, 2025, a decrease of -36.70%. This brings the company's revenue in the last twelve months to 178.61M, down -5.69% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
178.61M SEK
Revenue Growth
-5.69%
P/S Ratio
19.05
Revenue / Employee
1.32M SEK
Employees
135
Market Cap
307.78M EUR
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Hansa Biopharma AB News
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript - Seeking Alpha
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases - Slideshow - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ... - GuruFocus
- 4 weeks ago - Q3 2025 Hansa Biopharma AB Earnings Call Transcript - GuruFocus
- 4 weeks ago - Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results - PRNewsWire
- 4 weeks ago - Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results - PRNewsWire